News

At ESC HF 2024 in Lisbon, during an oral presentation, new data data of our CRF2 peptide agonist COR-1167 were released. On top of furosemide, COR-1167 reduced elevated cardiac filling and venous pressures, increased diuresis, decreased body weight and improved renal function in a worsening heart failure sheep model, even under conditions of fluid

Corteria team is very proud to announce the initiation of COR-1167 first-in-human study. COR-1167 is a first-in-class corticotropin-releasing hormone receptor 2 (CRF2) agonist. A significant milestone toward a treatment for worsening heart failure. Full PR is available here :https://corteriapharma.com/wp-content/uploads/2024/03/Corteria-PR-FIM-COR-1167-EN.pdf

Paris (France), 05 January 2024 – Corteria Pharmaceuticals (“Corteria”), a biopharmaceutical company specialized in the development of transformative therapies for heart failure and obesity, today announced it has appointed Mark Pruzanski, MD, as Chairman of its Board of Directors. He replaces Thierry Laugel, Managing Partner at Kurma Partners, who remains a member of the

At AHA 2023, the last results of COR-1167 in a sheep model of Worsening Heart Failure, developed by M. Rademaker (Univ. Otago, NZ) were presented: Furosemide at a dose that promotes natriuresis/diuresis had no effect on cardiac pressures or function. The combination of COR-1167 plus furosemide reduced Left Atrial Pressure, Left Ventricular End Diastolic

Paris (France), 07 September 2023 – Corteria Pharmaceuticals (“Corteria”), a biopharmaceutical company specialized in the development of transformative therapies for unaddressed heart failure subpopulations, today announced an oversubscribed €65M ($71M1) Series A co-led by US investment firm OrbiMed and EU-based leading investment firm Jeito Capital, with the participation of all existing seed investors (Kurma

At ESC 2023, the acute effects of the new long-acting CRF2 selective agonist COR-1167 in a rat model of heart failure with reduced ejection fraction were presented for the first time ! COR-1167 rapidly improved cardiac function through its mild positive inotropic and marked lusitropic effects after a single subcutaneous injection demonstrating that CRF2 receptor

Instead of targeting broad heterogenous chronic heart failure populations, at Corteria, we are addressing well defined heart failure subpopulations that are most likely to benefit from our treatments: learn more about Corteria Pharmaceuticals strategy and portfolio at https://lnkd.in/gncbAv4r

Corteria Pharmaceuticals team is growing with the arrival of two very valuable members: Eléonore Jouanny who will be in charge of the CMC activities of our assets and Stephane Durant des Aulnois who is our new CFO…

Francesca is a physician with 30+ years’ experience in drug development encompassing phase 1 through phase 3 registrational trials and life cycle management. Her specialized expertise is in cardio-metabolic diseases. She joined Corteria from Applied Therapeutics, a clinical-stage biotechnology company, where, as the Head of Development and later VP, Clinical and Regulatory Strategy, she